Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Le, Long P ^a   Dias Santagata, Dora ^a   Pawlak, Amanda C ^a   Cosper, Arjola K ^a   Nguyen, Anh Thu ^a   Selim, M Angelica ^b   Deng, April ^c   Horick, Nora K ^a   Iafrate, A John ^a   Mihm, Martin C ^d   Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; AGGRESSIVE DIGITAL PAPILLARY ADENOCARCINOMA; AKT 1 GENE; APOCRINE CARCINOMA; ARTICLE; CHONDROID HIDRADENOMA; CONTROLLED STUDY; ECCRINE POROCARCINOMA; EGFR GENE; ERBB2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HIDRADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PIK3CA GENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SWEAT GLAND CARCINOMA; SWEAT GLAND TUMOR; TP53 GENE; TRISOMY; TUMOR GENE;

EID: 84867304954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047290     Document Type: Article

References (60)

1. LeBoit PE, Burg G, Weedon D, Sarsin A (eds) (2006) World Health Organization Classification of Tumors: Pathology & Genetics: Skin Tumors. Lyon, France: IARC Press.
2. Blake PW, Bradford PT, Devesa SS, Toro JR, (2010) Cutaneous appendageal carcinoma incidence and survival patterns in the United States: A population-based study. Arch Dermatol 146: 625-632.
3. Robson A, Greene J, Ansari N, Kim B, Seed PT, et al. (2001) Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 25: 710-720.
4. Wong TY, Suster S, Nogita T, Duncan LM, Dickersin RG, et al. (1994) Clear cell eccrine carcinomas of the skin: a clinicopathologic study of nine patients. Cancer 73: 1631-43.
5. Duke WH, Sherrod TT, Lupton GP, (2000) Aggressive digital papillary adenocarcinoma (aggressive digital papillary adenoma and adenocarcinoma revisited). Am J Surg Pathol 24: 775-784.
6. Battistella M, Mateus C, Lassau N, Chami L, Boukoucha M, et al. (2010) Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol 24: 199-203.
7. Nash JW, Barrett TL, Kies M, Ross MI, Sneige N, et al. (2007) Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications. J Cutan Pathol 34: 49-54.
8. Schroder U, Dries V, Klussmann JP, Wittekindt C, Eckel HE, (2004) Successful adjuvant tamoxifen therapy for estrogen receptor-positive metastasizing sweat gland adenocarcinoma: need for a clinical trial? Ann Otol Rhinol Laryngol 113: 242-4.
9. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-48.
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-45.
11. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosinase kinase inhibitors. Cancer Cell 10: 25-38.
12. Li D, Ambrogo L, Shimamura T, Kubo S, Takahashi M, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-11.
13. Riely GJ (2008) Second-generation epidermal growth factor receptor tyrosinase kinase inhibitors in non-small cell lung cancer. J Thorac Oncol (Suppl 2): S146-S149.
14. Adelson K, Germain D, Raptis G, Biran N, (2011) Hormonal modulation in the treatment of breast cancer. Endocrinol Metab Clin North Am 40: 519-32.
15. Biernat W, Peraud A, Wozniak L, Ohqaki H, (1998) p53 mutations in sweat gland carcinomas. Int J Cancer 76: 317-20.
16. Dias-Santagata D, Lam Q, Bergethon K, Baker GM, Iafrate AJ, et al. (2011) A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Mod Pathol 24: 974-982.
17. Kazakov DV, Ivan D, Kutzner H, Spagnolo DV, Grossmann P, et al. (2009) Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t (11;19) translocation. Am J Dermatopathol 31: 236-47.
18. Takata M, Hashimoto K, Mehregan P, Lee MVV, Yamamoto A, et al. (2000) Genetic changes in sweat gland carcinomas. J Cutan Pathol 27: 30-5.
19. Takata M, Rehman I, Rees JL, (1998) A trichilemmal carcinoma arising from a proliferating trichilemmal cyst: the loss of the wild-type p53 is a critical event in malignant transformation. Hum Pathol 29: 193-5.
20. Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, et al. (2010) Epidermal growth factor receptor gene status by fluorescent in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol 32: 586-92.
21. Busam KJ, Tan LK, Granter SR, Kohler S, Junkins-Hopkins J, et al. (1999) Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol 12: 786-93.
22. Robson A, Lazar AJ, Ben Nagi J, Hanby A, Grayson W, et al. (2008) Primary cutaneous apocrine carcinoma: a clinicopathologic analysis of 24 cases. Am J Surg Pathol 32: 682-690.
23. Swanson PE, Mazoujian G, Mills SE, Campbell RJ, Wick MR, (1991) Immunoreactivity for estrogen receptor protein in sweat gland tumors. Am J Surg Pathol 15: 835-41.
24. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, et al. (2010) Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2: 146-58.
25. Janisson-Dargaud D, Durlach A, Lorenzato M, Grange F, Bernard P, et al. (2008) Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol 35: 916-21.
26. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, et al. (2008) Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 111: 289-97.
27. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
28. Gatalica Z, (1997) Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progresterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 193: 753-758.
29. Tavassoli FA, Purcell CA, Bratthauer GL, Man Y, (1996) Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J 2: 261-269.
30. Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ, (1992) Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 133: 467-475.
31. Jaspers HCJ, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, et al. (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29: e473-6.
32. Li AR, Chitale D, Riely GJ, Pao W, Miller VA, et al. (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10: 242-248.
33. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer (Suppl 4): 9-15.
34. Ettl T, Stiegler C, Zeitler K, Muller M, Agaimy A, et al. (2011) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol in press.
35. Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, et al. (2012) High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 18: 1760-8.
36. Berns EM, Klijn JG, Smid M, van Staveren IL, Look MP, et al. (1996) TP53 and myc gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 16: 170-9.
37. Elledge RM, Allred DC, (1994) The P53 tumor suppressor genes in breast cancer. Breast Cancer Res Treat 32: 39-47.
38. Hollstein M, Sidransky D, Vogelstain B, Harris CC, (1991) p53 mutations in human cancer. Science 253: 49-53.
39. Levine AJ, (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-31.
40. Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, et al. (2012) High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 106: 397-404.
41. Rapakko K, Allinen M, Syrjakoski K, Vahteristo P, Huusko P, et al. (2001) Germline TP53 alterations in Finish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 84: 116-9.
42. Ruijs MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, et al. (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 47: 421-8.
43. Michelucci A, Cristofano CD, Lami A, Collecchi P, Caligo A, et al. (2009) PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 18: 200-5.
44. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
45. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL (2005) PIK3CA mutations in advanced ovarian carcinomas. Human Mutation #787 online.
46. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-5.
47. Samuels Y, Ericson K, (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 18: 77-82.
48. Chin L, Gray JW, (2008) Translating insights from the cancer genome into clinical practice. Nature 452: 553-63.
49. Turke AB, Engelman JA, (2010) PIKing the right patient. Clin Cancer Res 169: 3523-5.
50. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, et al. (2009) Mutations in the phophatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69: 143-50.
51. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-30.
52. Vivanco I, Sawyers CL, (2002) The phosphatidyl inositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
53. Morgensztern D, McLeod HL, (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803.
54. Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, et al. (2006) Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 70: 285-289.
55. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. (2008) An intergrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
56. de Giorgi V, Sestini S, Massi D, Papi F, Lotti T, (2007) Eccrine porocarcinoma: a rare but sometimes fatal malignant neoplasm. Dermatol Surg 33: 371-377.
57. Gutermuth J, Audring H, Voit C, Trefzer U, Haas N, (2004) Antitumor activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol 18: 477-9.
58. Tlemcani K, Levine D, Smith RV, Brandwein-Gensler M, Staffenberg DA, et al. (2010) Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J Clin Oncol 28: e412-4.
59. Zeidan YH, Zauls AJ, Belic M, Lentsch EJ, Sharma AK, (2010) Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report. J Med Case Reports 4: 147.
60. Hidaka T, Fujimura T, Watabe A, Hashimoto A, Haga T, et al. (2012) Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with Lapatinib and Capecitabine. Acta Derm Venereol In press.